Patent · US Active

TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors

US12281152B2 · kind B2 · utility

0Cited by
4References
42Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 1, 2019
Grant dateApr 22, 2025
Priority date—
Expiry dateFeb 20, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2501/20
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Chimeric antigen receptors targeted to TAG72 and the use thereof to treat ovarian cancer and other cancers are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.